ChemoCentryx stock jumps 80% after receiving FDA approval for vasculitis drug

by



[ad_1]

Shares of ChemoCentryx Inc. CCXI,
+ 68.11%
jumped 80.3% in pre-market trading on Friday after the company said it received Food and Drug Administration approval for its treatment of vasculitis associated with ANCA. The company said it was the first new drug to treat the rare autoimmune disease in a decade. ChemoCentryx stock has fallen 68.3% this year, while the larger S&P 500 SPX stock,
+ 0.05%
is up 16.1%.

[ad_2]

Source link